--- canonical_name: Niacinamide alternate_names: Nicotinamide, Vitamin B3, Niacin Amide, Nicotinic Acid Amide, 3-Pyridinecarboxamide canonical_topic: Niacinamide for Health & Longevity short_topic_lc: niacinamide creation_date: 2026-0709-1628 creator_ai_fullname: Opus 4.8 ep_keywords: NAD+ Precursors, B Vitamins, Vitamins --- # Niacinamide for Health & Longevity

Evidence Review created on 07/09/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** Nicotinamide, Vitamin B3, Niacin Amide, Nicotinic Acid Amide, 3-Pyridinecarboxamide ## Motivation Niacinamide (also called nicotinamide, one of the two main forms of vitamin B3) is an inexpensive, water-soluble nutrient found in food and sold as an oral supplement and a common skincare ingredient. Inside the body it is a building block for a coenzyme that every cell uses to turn food into energy and to repair damaged DNA. Unlike its cousin niacin, niacinamide does not cause the uncomfortable skin flushing that limits high-dose niacin, which has made it attractive for the higher intakes used in research. Long recognized for correcting vitamin B3 deficiency, niacinamide has drawn fresh interest for two very different reasons. A landmark skin-cancer prevention trial showed that ordinary oral doses lowered the rate of new non-melanoma skin cancers in high-risk people, and the aging-research community has explored whether topping up the same coenzyme could slow features of aging. This review examines what the evidence shows about niacinamide across these uses, how strong that evidence is, where results conflict, and what practical, dosing, safety, and monitoring considerations matter for health- and longevity-focused readers weighing it. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section collects high-level expert and narrative resources that give directly relevant, in-depth context on niacinamide and its role as a vitamin B3 and NAD+ (nicotinamide adenine dinucleotide, a coenzyme every cell uses for energy metabolism and DNA repair) precursor. * [Evaluating NAD and NAD precursors for health and longevity](https://peterattiamd.com/nad-for-health-and-longevity/) - Peter Attia A measured, skeptical walkthrough of why NAD+ matters biologically and why the human longevity case for boosting it (including with vitamin B3 forms) remains unproven, useful for calibrating expectations around niacinamide as a longevity tool. * [NAD+ in Aging: Role of Nicotinamide Riboside and Nicotinamide Mononucleotide](https://www.foundmyfitness.com/episodes/nad-nr-nmn) - Rhonda Patrick A detailed overview of NAD+ biology and how the different vitamin B3 forms — including nicotinamide (niacinamide) — feed into NAD+, clarifying where the strongest human evidence does and does not exist. * [Nutrition for Healthy Skin: Silica, Niacin, Vitamin K2, and Probiotics](https://chriskresser.com/nutrition-for-healthy-skin-silica-niacin-vitamin-k2-and-probiotics/) - Chris Kresser A functional-medicine perspective on niacin and niacinamide for skin health, including its topical use for acne, that complements the clinical trial data covered later in this review. * [What Has Scientists Excited About NAD+](https://www.lifeextension.com/magazine/2021/7/nad-nicotamine-riboside-benefits) - Jeff Simmons A consumer-facing longevity article summarizing why declining NAD+ is a target for aging interventions and how vitamin B3 derivatives are positioned within that strategy. * [Mechanistic Basis and Clinical Evidence for the Applications of Nicotinamide (Niacinamide) to Control Skin Aging and Pigmentation](https://pubmed.ncbi.nlm.nih.gov/34439563/) - Boo, 2021 A thorough narrative review dedicated specifically to niacinamide, detailing how it restores cellular NAD+, supports the skin barrier, and reduces pigmentation, with the clinical evidence behind each effect. ## Grokipedia * [Niacinamide](https://grokipedia.com/page/Niacinamide) Grokipedia's dedicated article provides a broad reference overview of niacinamide's chemistry, biological role as an NAD+ precursor, and its dermatological and clinical uses. ## Examine * [Nicotinamide](https://examine.com/supplements/nicotinamide/) Examine's evidence-graded page summarizes the human research on oral and topical nicotinamide, including studied dose ranges (25 mg to 6 g/day), skin benefits, and its generally favorable tolerability. ## ConsumerLab * [Latest Information About Niacin/Niacinamide/Other: Product Reviews, Warnings, Recalls, & Clinical Updates](https://www.consumerlab.com/niacinniacinamideother/) ConsumerLab's niacin/niacinamide hub aggregates independent product testing, dosing and safety answers, and clinical updates relevant to choosing a quality niacinamide or B-vitamin supplement. ## Systematic Reviews This section presents the most relevant recent systematic reviews and meta-analyses of niacinamide, prioritized by relevance, study size, and recency. * [Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis.](https://pubmed.ncbi.nlm.nih.gov/35134311/) - Mainville et al., 2022 Pools randomized and observational data on oral nicotinamide for preventing non-melanoma skin cancer and actinic keratosis (rough precancerous skin patches), and specifically catalogs its adverse-effect profile, making it the most directly relevant safety-and-efficacy synthesis for the strongest use case. * [The Role of Nicotinamide as Chemo-Preventive Agent in NMSCs: A Systematic Review and Meta-Analysis.](https://pubmed.ncbi.nlm.nih.gov/38201930/) - Tosti et al., 2023 A more recent meta-analysis focused on non-melanoma skin cancer (NMSC) chemoprevention that weighs the positive immunocompetent-population data against weaker results in higher-risk groups such as transplant recipients. * [Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review.](https://pubmed.ncbi.nlm.nih.gov/37971292/) - Gindri et al., 2024 Reviews human trials of NAD+ and its precursors (including nicotinamide) across metabolic, neurological, and other conditions, providing a broad reality-check on where clinical benefit is and is not established. * [Topical treatment for postinflammatory hyperpigmentation: a systematic review.](https://pubmed.ncbi.nlm.nih.gov/34525885/) - Tan et al., 2022 Evaluates topical agents including niacinamide for dark spots left after inflammation, supporting the dermatologic pigmentation evidence and clarifying niacinamide's modest, adjunctive effect size. * [NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.](https://pubmed.ncbi.nlm.nih.gov/41655607/) - Gallagher & Emmanuel, 2026 Systematically contrasts the strong preclinical longevity signal for NAD+ boosting with the thin and inconsistent human evidence, directly relevant to niacinamide's speculative longevity positioning. ## Mechanism of Action Niacinamide is the amide form of vitamin B3. Its central role is to serve as a precursor to nicotinamide adenine dinucleotide (NAD+, a coenzyme every cell uses to convert food into usable energy and to repair DNA) and its phosphorylated relative NADP (the same coenzyme carrying an extra phosphate, used mainly in antioxidant defense and building fats). The primary pathways are: * **NAD+ salvage pathway:** Niacinamide is recycled into NAD+ chiefly through the enzyme nicotinamide phosphoribosyltransferase (NAMPT, the rate-limiting enzyme that regenerates NAD+ from nicotinamide). Because most tissues rely on this salvage route rather than building NAD+ from scratch, supplying niacinamide can support cellular NAD+ pools that decline with age and metabolic stress. * **Support of NAD+-consuming enzymes:** NAD+ is consumed by DNA-repair enzymes called poly(ADP-ribose) polymerases (PARPs) and by sirtuins (a family of enzymes involved in DNA repair, inflammation control, and metabolic regulation that require NAD+ to work). By feeding the NAD+ pool, niacinamide can indirectly support these systems. * **Skin and antioxidant effects:** In skin, restoring NAD+/NADP levels improves the energy supply of skin cells, strengthens the barrier by boosting ceramide and other lipid production, dampens inflammation, and interrupts the transfer of pigment to surface skin cells — the basis for its cosmetic effects. A competing and important nuance runs the other way. Nicotinamide is also a direct product-inhibitor of sirtuins and PARPs: at high tissue concentrations it can partially block the very sirtuin activity that longevity researchers hope to enhance. This is why simply raising nicotinamide does not straightforwardly "activate" the longevity pathways, and why some researchers argue that other vitamin B3 forms, or tighter dose control, may matter. The evidence here is mechanistic and remains debated. Key pharmacological properties: * **Half-life and distribution:** Oral niacinamide is rapidly and almost completely absorbed, has a plasma half-life of roughly 3.5–4 hours, is widely distributed in body water, crosses the blood–brain barrier, and shows minimal protein binding. * **Metabolism and elimination:** Beyond salvage into NAD+, excess nicotinamide is metabolized in the liver by nicotinamide N-methyltransferase (NNMT, the enzyme that disposes of surplus nicotinamide by attaching a methyl group), producing 1-methylnicotinamide and pyridone metabolites that are excreted by the kidneys. It is not a meaningful substrate for the cytochrome P450 (CYP, the liver's main drug-metabolizing enzyme family) system, so classic CYP drug interactions are minimal; its most relevant metabolic footprint is consumption of methyl groups. ## Historical Context & Evolution * **Original use — deficiency disease:** Niacinamide's original and still-valid use is the prevention and treatment of pellagra, the vitamin B3 deficiency disease marked by dermatitis, diarrhea, dementia, and, untreated, death. After Joseph Goldberger's early 20th-century work linked pellagra to diet and the "pellagra-preventive factor" was identified as niacin/niacinamide, food fortification largely eradicated the disease in developed countries. Niacinamide was favored over niacin in some contexts because it does not cause flushing. * **Move into optimization and dermatology:** Interest broadened as researchers recognized that niacinamide's downstream product, NAD+, is central to energy metabolism, DNA repair, and cellular stress responses. In dermatology, topical niacinamide became a mainstream cosmetic active for barrier support, oil control, and pigmentation. In oncology-adjacent prevention, the finding that oral niacinamide could reduce new skin cancers in high-risk patients moved it from vitamin to studied preventive agent. * **Findings, not just reception:** The historical skin-cancer signal rests on actual randomized data — most notably a trial in which 500 mg twice daily reduced new non-melanoma skin cancers over 12 months in people with prior lesions. Rather than treat this as settled or overturned, it should be read alongside a later randomized trial in organ-transplant recipients that found no benefit, indicating the effect may depend on immune status and population. * **Evolving opinion:** Enthusiasm for niacinamide as a systemic longevity-oriented NAD+ booster has been tempered as human trials failed to reproduce dramatic preclinical effects, and as the sirtuin-inhibition paradox became better appreciated. At the same time, its dermatologic and skin-cancer-prevention roles have strengthened. The current picture is one of a well-tolerated vitamin with a few solid, targeted uses and a much larger set of speculative ones — a standing that continues to shift as large trials in glaucoma and other areas report. ## Expected Benefits Benefits are framed for risk-aware, proactive adults considering niacinamide to optimize health or longevity, and are grouped by the strength of the underlying evidence. ### High 🟩 🟩 🟩 #### Non-Melanoma Skin Cancer & Actinic Keratosis Chemoprevention ⚠️ Conflicted In people with a history of sun-related skin cancers, oral niacinamide reduces the rate of new non-melanoma skin cancers (basal and squamous cell) and actinic keratoses (rough precancerous patches). The proposed mechanism is enhanced DNA repair and prevention of ultraviolet-induced depletion of cellular energy in skin cells. The strongest evidence is a double-blind randomized controlled trial (a study that randomly assigns participants to treatment or placebo) plus pooling meta-analyses in immunocompetent high-risk adults. Evidence is conflicted because a later randomized trial in organ-transplant recipients found no significant benefit, suggesting the effect depends on immune status and baseline risk. **Magnitude:** ~23% relative reduction in new non-melanoma skin cancers and ~13% fewer actinic keratoses at 12 months with 500 mg twice daily; no significant benefit in the transplant-recipient trial. #### Prevention and Treatment of Vitamin B3 Deficiency Niacinamide reliably prevents and reverses pellagra and other states of vitamin B3 insufficiency by restoring NAD+/NADP synthesis. This is the foundational, non-controversial use, supported by a century of clinical experience and its inclusion in food-fortification programs. It is relevant to the target audience mainly for those with malabsorption, alcohol use disorder, or restrictive diets. **Magnitude:** Doses of 25–100 mg/day fully prevent deficiency and resolve pellagra symptoms, typically within days to weeks. ### Medium 🟩 🟩 #### Topical Skin Barrier, Pigmentation, and Aging Appearance Applied to the skin, niacinamide strengthens the barrier (by increasing ceramide production), reduces water loss, lowers sebum, and fades hyperpigmentation and post-inflammatory dark spots by interrupting pigment transfer. Multiple small-to-moderate randomized trials and systematic reviews support modest but consistent cosmetic improvements. Effects build over weeks and are adjunctive rather than dramatic; most positive studies use 2–5% topical formulations, sometimes combined with other actives. **Magnitude:** Measurable reductions in hyperpigmentation, transepidermal water loss, and fine-line appearance over 4–12 weeks; effect sizes are modest and formulation-dependent. #### Serum Phosphate Reduction in Chronic Kidney Disease Oral niacinamide lowers serum phosphate by inhibiting sodium-dependent phosphate transporters in the gut, offering a non-binder mechanism for phosphate control in chronic kidney disease (CKD, long-term loss of kidney filtering capacity). Randomized trials in dialysis populations show meaningful phosphate lowering, though tolerability and platelet effects limit enthusiasm. This benefit is most relevant to the subset of the audience managing kidney disease rather than the general longevity-focused reader. **Magnitude:** Reductions in serum phosphate of roughly 0.5–1.0 mg/dL at 750–1,500 mg/day in dialysis trials. ### Low 🟩 #### Neuroprotection in Glaucoma Emerging human data suggest high-dose oral niacinamide may protect retinal ganglion cells (the eye's output neurons) in glaucoma by supporting their NAD+-dependent energy metabolism. A small crossover randomized trial reported improved inner-retinal function on electrical testing, and large confirmatory trials are underway. The evidence is currently limited to short-term surrogate outcomes rather than long-term preservation of vision. **Magnitude:** Improved inner-retinal function on electroretinography with doses up to 3 g/day in a small crossover trial; visual-field outcomes not yet established. #### Acne (Topical and Oral) Niacinamide has anti-inflammatory and sebum-reducing properties that can improve inflammatory acne, with topical 4% formulations performing comparably to some topical antibiotics in small trials. It is generally used as an adjunct rather than a primary acne therapy, and oral evidence is weaker than topical. **Magnitude:** Comparable reduction in inflammatory acne lesions to topical clindamycin in small head-to-head trials; overall effect modest. ### Speculative 🟨 #### Systemic NAD+ Restoration and Longevity The hope that oral niacinamide meaningfully raises systemic NAD+ and slows aging is supported mainly by preclinical models and mechanistic reasoning, not by robust human longevity outcomes. Oral nicotinamide is a comparatively weak systemic NAD+ booster and, at high doses, can inhibit the sirtuin enzymes that longevity strategies aim to enhance. Human trials to date show inconsistent NAD+ elevation and no demonstrated effect on aging endpoints, so this remains hypothesis-generating. #### Neuroprotection in Neurodegenerative Disease Niacinamide is being explored for Parkinson's, Alzheimer's, and related conditions on the premise that supporting neuronal NAD+ could slow degeneration. Current support is mechanistic and drawn from animal models and small pilots; no controlled human data establish clinical benefit, and some trials combine it with other agents, making attribution difficult. ## Benefit-Modifying Factors * **Baseline vitamin B3 / NAD+ status:** People who are deficient or depleted (poor diet, alcohol use disorder, malabsorption) stand to gain the most from correction, whereas replete individuals see little added metabolic benefit from routine supplementation. * **Immune status:** The skin-cancer chemoprevention benefit appears robust in immunocompetent high-risk individuals but was not confirmed in immunosuppressed organ-transplant recipients, making immune status a key modifier. * **Cumulative sun damage and skin-cancer history:** The chemoprevention effect is most relevant and measurable in those with prior non-melanoma skin cancers or heavy actinic damage; low-risk individuals have little to gain. * **Genetic polymorphisms in methylation (MTHFR, COMT):** Because high-dose niacinamide consumes methyl groups, people with reduced methylation capacity — e.g., variants in MTHFR (an enzyme that activates folate for methylation) or COMT (an enzyme that breaks down catecholamines using methyl groups) — may deplete methyl donors faster, potentially blunting tolerability and any benefit that depends on healthy methylation. * **Sex-based differences:** Data specific to niacinamide are limited; NAD+ metabolism and NNMT expression differ modestly by sex and body composition, but no clinically established sex-specific benefit difference has been demonstrated. * **Age:** Older adults, who have lower baseline NAD+ and higher skin-cancer and glaucoma risk, are the group in whom the targeted benefits (skin cancer prevention, retinal protection) are most plausibly relevant, though age-specific dosing data are sparse. ## Potential Risks & Side Effects Risks are framed for the target audience and grouped by the strength of the underlying evidence. Niacinamide is generally well tolerated at nutritional and moderate doses; most concerns arise at multi-gram daily intakes. ### High 🟥 🟥 🟥 #### Gastrointestinal Upset at High Doses Nausea, diarrhea, and abdominal discomfort are the most commonly reported side effects and are dose-dependent, becoming frequent at multi-gram daily intakes. The mechanism is local gastrointestinal irritation and osmotic effects. These effects are generally reversible on dose reduction and are the main tolerability limit in phosphate-lowering and glaucoma trials. **Magnitude:** Common above roughly 3 g/day; infrequent at typical supplemental doses of 500 mg or less. ### Medium 🟥 🟥 #### Hepatotoxicity at High Doses Sustained high-dose niacinamide can cause reversible elevations in liver enzymes and, rarely, clinically significant liver injury. The proposed mechanism includes methyl-group depletion and metabolic stress on the liver. Case reports and trial monitoring indicate the risk is concentrated at doses above 3 g/day and is usually reversible on discontinuation. Although niacinamide is less flushing and generally less hepatotoxic than sustained-release niacin, liver monitoring is prudent at high doses. **Magnitude:** Transaminase elevations mainly above 3 g/day; overt hepatotoxicity rare and largely limited to sustained gram-level dosing. #### Methyl-Group (Methylation) Depletion Because excess nicotinamide is cleared by methylation using S-adenosylmethionine (SAMe, the body's main methyl-group donor), chronic high doses increase demand for methyl groups and can raise homocysteine (an amino acid tied to cardiovascular risk when elevated). This is a measurable biochemical effect and a plausible route to downstream harm, though clinical consequences at moderate doses are not established. **Magnitude:** High doses increase urinary methylated metabolites and can modestly raise homocysteine; effect scales with dose and low folate/B12 status. #### Thrombocytopenia in Kidney-Disease Dosing In dialysis and chronic-kidney-disease trials using niacinamide for phosphate control, dose-dependent reductions in platelet count (thrombocytopenia, low platelets) have been observed. The mechanism is not fully defined but appears specific to sustained higher dosing in this population, warranting platelet monitoring where niacinamide is used therapeutically. **Magnitude:** Platelet reductions reported at 1–1.5 g/day in dialysis trials; generally reversible on dose reduction. ### Low 🟥 #### Glucose and Insulin Effects at Very High Doses Very high doses of niacinamide have been associated with small increases in fasting glucose and insulin resistance in some studies, likely through effects on NAD+-dependent metabolic signaling. The effect is inconsistent and appears minor at typical supplemental doses, but is relevant to those with prediabetes using gram-level intakes. **Magnitude:** Small, inconsistent increases in fasting glucose/insulin resistance mainly at gram-level dosing. #### Headache, Dizziness, and Minor Neurologic Complaints Mild headache, dizziness, and fatigue are occasionally reported, generally at higher doses and usually self-limiting. These are nonspecific and rarely lead to discontinuation. **Magnitude:** Infrequent and mild; more likely at higher doses. ### Speculative 🟨 #### Theoretical Cancer-Promotion Concern from NAD+ Boosting There is a theoretical worry that agents raising NAD+ could support the growth of existing cancers, since proliferating tumor cells have high NAD+ demand. This concern is mechanistic and drawn from laboratory reasoning; it has not been demonstrated as a clinical harm for niacinamide in humans, and the same compound shows cancer-preventive effects in skin. #### Sirtuin Inhibition Offsetting Longevity Goals At high tissue concentrations, nicotinamide directly inhibits sirtuin enzymes, which could theoretically counteract the metabolic and longevity benefits sought by NAD+ strategies. This is a mechanistic hypothesis without established clinical outcomes, but it is a reason high-dose use may not deliver expected longevity effects. ## Risk-Modifying Factors * **Methylation genetics (MTHFR, COMT):** Individuals with reduced methylation capacity may be more prone to homocysteine elevation and reduced tolerability at high doses, since niacinamide clearance draws on methyl donors. * **Baseline liver function and biomarkers:** Pre-existing elevated transaminases or fatty liver may increase susceptibility to dose-related liver enzyme elevation; baseline homocysteine, folate, and B12 status modify methylation risk. * **Sex-based differences:** No clearly established sex-specific risk differences exist for niacinamide, though differences in body size and NNMT activity may influence exposure at a given dose. * **Pre-existing health conditions:** People with chronic kidney disease (platelet effects), prediabetes or diabetes (glucose effects), and liver disease warrant closer monitoring and generally lower dosing. * **Age:** Older adults may have reduced hepatic and renal clearance and higher polypharmacy, modestly increasing the chance of side effects at high doses; nutritional doses remain well tolerated. ## Key Interactions & Contraindications * **Anticonvulsants (carbamazepine, primidone):** Niacinamide can inhibit their metabolism and raise blood levels. **Severity:** caution/monitor. **Consequence:** possible drug toxicity. **Mitigation:** monitor drug levels if combined at high niacinamide doses. * **Other hepatotoxic drugs or sustained-release niacin:** Combining high-dose niacinamide with drugs that stress the liver, or with sustained-release nicotinic acid, may compound liver risk. **Severity:** caution. **Consequence:** additive liver enzyme elevation. **Mitigation:** avoid stacking high-dose vitamin B3 forms; monitor liver enzymes. * **Over-the-counter agents (acetaminophen, alcohol):** Because both burden hepatic metabolism, heavy concurrent use with high-dose niacinamide is best avoided. **Severity:** caution. **Consequence:** increased liver stress. **Mitigation:** limit alcohol; use lowest effective niacinamide dose. * **Supplement interactions and additive effects:** Other NAD+ precursors (nicotinamide mononucleotide, NMN; nicotinamide riboside, NR) and nicotinic acid overlap in pathway and can push methylation demand higher when combined; methyl-donor supplements (folate, B12, methionine, betaine, choline) have additive, mitigating value by replenishing methyl groups consumed during niacinamide clearance. **Severity:** monitor. **Consequence:** compounded methyl depletion (with other B3 forms) or offsetting benefit (with methyl donors). **Mitigation:** avoid unnecessary stacking of B3 forms; pair sustained high doses with methyl-donor nutrients. * **Phosphate binders (in kidney disease):** Niacinamide's phosphate-lowering effect is additive with binders. **Severity:** monitor. **Consequence:** possible over-suppression of phosphate and additive platelet effects. **Mitigation:** monitor serum phosphate and platelets and adjust doses. * **Populations who should avoid or use caution:** People with active liver disease or unexplained transaminase elevations, those with a bleeding disorder or thrombocytopenia (platelet count <100 × 10⁹/L), pregnant or breastfeeding individuals taking above nutritional doses, and dialysis patients without monitoring should avoid high-dose use. Nutritional doses (up to the tolerable upper intake level of 35 mg/day of added niacin equivalents in many guidelines, higher for niacinamide specifically) are broadly safe. ## Risk Mitigation Strategies * **Start low and use the lowest effective dose:** Because nearly all meaningful risks (gastrointestinal, liver, methylation, platelet) are concentrated at multi-gram intakes, using 500 mg/day or less where that suffices (e.g., skin-cancer chemoprevention at 500 mg twice daily) minimizes harm while retaining the best-evidenced benefit. * **Co-supplement methyl donors at high doses:** To offset methyl-group depletion and homocysteine elevation, pair sustained high-dose niacinamide with folate, vitamin B12, and possibly betaine or choline, and confirm adequate status by testing. * **Monitor liver enzymes on high-dose regimens:** For anyone using ≥1.5–3 g/day, check baseline and periodic transaminases (ALT/AST) to catch reversible elevations early and stop or reduce dose if they rise. * **Monitor platelets in kidney-disease use:** When niacinamide is used for phosphate control, track platelet counts (e.g., at baseline, then every 4–8 weeks initially) to detect dose-related thrombocytopenia and adjust accordingly. * **Screen glucose in metabolically vulnerable users:** For prediabetic or diabetic individuals using gram-level doses, monitor fasting glucose and HbA1c (glycated hemoglobin, a measure of average blood sugar over roughly three months) to detect any worsening of insulin resistance. * **Avoid stacking multiple vitamin B3 forms:** Do not combine high-dose niacinamide with nicotinic acid, NMN, or NR simultaneously, which compounds methylation demand without clear added benefit. ## Therapeutic Protocol * **Skin-cancer chemoprevention (best-evidenced use):** Leading dermatology practice, following the pivotal trial, uses oral niacinamide 500 mg twice daily in high-risk immunocompetent adults with a history of non-melanoma skin cancer or actinic keratoses. * **General supplemental / deficiency correction:** Nutritional and repletion doses range from 25–100 mg/day; there is no established need for high doses in replete, low-risk individuals. * **Dermatologic (topical) use:** For barrier, pigmentation, and acne goals, topical 2–5% niacinamide applied once or twice daily is the standard approach, popularized widely in cosmetic dermatology and often combined with other actives. * **Investigational high-dose uses:** Glaucoma neuroprotection protocols in trials use higher doses (up to ~1.5–3 g/day, often titrated); phosphate control in kidney disease uses ~750–1,500 mg/day. These are conducted under medical supervision, not as self-directed longevity regimens. * **Competing approaches without a forced default:** For raising NAD+, alternatives include nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), championed by parts of the longevity-research community, versus niacinamide's simplicity and low cost; none is established as superior for human longevity outcomes, and each is presented here as an option rather than a recommendation. * **Best time of day:** No strong circadian requirement exists; some users take niacinamide in the evening for its historical mild calming effect, while split dosing (e.g., twice daily) is used in the chemoprevention protocol to maintain levels. * **Half-life consideration:** With a plasma half-life of roughly 3.5–4 hours, twice-daily dosing is used when steady exposure matters (as in the skin-cancer trial), whereas once-daily suffices for basic repletion. * **Genetic, sex, age, biomarker, and condition tailoring:** Methylation-relevant variants (MTHFR, COMT) argue for co-supplementing methyl donors at high doses; older adults and those with liver, kidney, or glucose issues favor lower doses with monitoring; no validated sex-specific dosing exists; baseline homocysteine, liver enzymes, and (in kidney disease) phosphate and platelets guide individualization. ## Discontinuation & Cycling * **Lifelong vs. short-term:** Use is typically ongoing while the goal persists (e.g., continuous 500 mg twice daily for skin-cancer risk reduction, since benefit does not clearly persist after stopping) rather than a fixed course; deficiency correction can be short-term once repletion is achieved. * **Withdrawal effects:** No physical dependence or withdrawal syndrome is described for niacinamide; stopping is not associated with rebound effects. * **Tapering:** No taper is required; the compound can be stopped abruptly without a weaning schedule. * **Cycling:** There is no established efficacy rationale for cycling niacinamide; however, some longevity users periodically pause high-dose regimens to limit methyl-donor depletion and to reassess need, which is a reasonable precaution rather than an evidence-based protocol. ## Sourcing and Quality * **Choose the correct form:** Ensure the label specifies "niacinamide" or "nicotinamide" rather than "niacin"/"nicotinic acid" (which causes flushing and has different effects) or "inositol hexanicotinate"; niacinamide is often marketed as "no-flush" but so are other forms, so verify the actual compound. * **Third-party testing:** Prefer products verified by independent testers (e.g., USP, NSF, or ConsumerLab) for identity and purity, since supplement labeling accuracy varies; niacinamide itself is inexpensive and stable, so quality issues are more about correct labeling and absence of contaminants than potency. * **Formulation and dose accuracy:** Simple tablets or capsules of plain niacinamide are preferred; be cautious with proprietary "NAD-boosting" blends that mix multiple B3 forms and other actives, which can obscure the actual niacinamide dose and increase methylation load. * **Reputable manufacturing:** Choose brands following good manufacturing practices; for therapeutic high-dose or investigational uses, pharmaceutical-grade nicotinamide obtained through a clinician or compounding pharmacy provides better dose control. ## Practical Considerations * **Time to effect:** Deficiency symptoms improve within days to weeks; topical skin benefits build over 4–12 weeks; skin-cancer risk reduction is measured over 12 months of continuous use; NAD+/longevity effects, if any, are not reliably observable by the individual. * **Common pitfalls:** Confusing niacinamide with flushing niacin; expecting large systemic longevity effects from oral dosing; using unnecessarily high doses that raise liver and methylation risk without added benefit; and neglecting methyl-donor status on high-dose regimens. * **Regulatory status:** Niacinamide is regulated as a dietary supplement and food-fortification ingredient (not a prescription drug) and is generally recognized as safe at nutritional levels; its high-dose uses in skin cancer, glaucoma, and kidney disease are off-label or investigational. * **Cost and accessibility:** Niacinamide is widely available and very inexpensive, which is a notable advantage over patented NAD+ precursors; cost is not a barrier for the target audience. ## Interaction with Foundational Habits * **Sleep:** Interaction is potentially **potentiating** (mild). Niacinamide has a historical reputation as a mild calming agent, with some evidence of benzodiazepine-like activity at brain receptors that regulate relaxation; some users take it in the evening, though robust sleep-outcome data are limited. Practical consideration: if used for a subtle calming effect, evening dosing is reasonable, but it is not an established sleep aid. * **Nutrition:** Interaction is **direct** and bidirectional. High-dose niacinamide consumes methyl groups, so a diet or supplement plan adequate in folate, B12, methionine, choline, and betaine mitigates homocysteine elevation; conversely, dietary tryptophan and preformed niacin contribute to the same NAD+ pool. Practical consideration: pair sustained high doses with methyl-donor-rich foods or supplements. * **Exercise:** Interaction is largely **indirect** and possibly **blunting** at high doses. Exercise itself raises NAD+ and sirtuin activity, and there is a theoretical concern that very high nicotinamide could inhibit sirtuins and mute some exercise adaptations, though this is not demonstrated in humans. Practical consideration: nutritional and moderate doses are not expected to interfere with training; avoid gram-level dosing around the goal of maximizing exercise adaptation absent evidence. * **Stress management:** Interaction is **indirect**. Through its historical calming reputation and its support of NAD+-dependent stress-response pathways, niacinamide is sometimes framed as stress-supportive, but controlled evidence on cortisol or stress outcomes is lacking. Practical consideration: treat any anxiolytic effect as anecdotal rather than relying on it for stress control. ## Monitoring Protocol & Defining Success Baseline testing before starting sustained or high-dose niacinamide establishes a reference for liver, methylation, and (where relevant) kidney and glucose status, so that dose-related changes can be detected. For low nutritional doses, extensive testing is generally unnecessary. Ongoing monitoring cadence for high-dose or therapeutic use: check relevant labs at baseline, then at approximately 4–8 weeks after starting or dose escalation, and thereafter every 6–12 months (more frequently, e.g., every 4–8 weeks, for platelets in kidney-disease dosing). | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | ALT / AST | ALT ~10–26 U/L; AST ~10–26 U/L | Detect dose-related liver stress | ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are liver enzymes; conventional upper limits (~40 U/L) are higher than functional targets; most relevant above ~1.5 g/day | | Homocysteine | <7–8 µmol/L | Track methyl-group depletion | Conventional "normal" extends to ~15 µmol/L; rises with high-dose B3 and low folate/B12; fasting sample preferred | | Fasting glucose | 75–86 mg/dL | Detect worsening insulin resistance | Conventional normal <100 mg/dL; monitor mainly at gram-level doses or in prediabetes; requires fasting | | HbA1c | <5.4% | Longer-term glucose control | Conventional threshold <5.7%; pairs with fasting glucose; not affected by fasting status | | Platelet count | 200–350 × 10⁹/L | Detect thrombocytopenia in therapeutic dosing | Conventional normal 150–400 × 10⁹/L; specifically relevant to kidney-disease phosphate-lowering use | | Serum phosphate | 3.0–4.0 mg/dL | Assess phosphate-lowering effect / avoid over-suppression | Only relevant when niacinamide is used for phosphate control in CKD; best drawn fasting | | Uric acid | 3.5–6.0 mg/dL (higher end for men) | High-dose vitamin B3 can raise uric acid | Conventional upper limit ~7 mg/dL; relevant at gram-level dosing, especially with gout history | Qualitative markers of success and tolerability to track alongside labs: * Skin appearance: fewer new actinic lesions, improved barrier, reduced hyperpigmentation * Gastrointestinal comfort: absence of nausea or diarrhea signaling excess dose * Energy and cognitive clarity: subjective, non-specific, and not a reliable NAD+ readout * Sleep quality: any subjective calming effect if used in the evening ## Emerging Research Research framed for proactive, longevity-oriented readers is advancing on several fronts, with major trials testing whether niacinamide's targeted benefits hold up and where its limits lie. * **Glaucoma neuroprotection (large phase III):** The [NAMinG trial (NCT05405868)](https://clinicaltrials.gov/study/NCT05405868) is a randomized, placebo-controlled, multi-centre phase III study of oral nicotinamide in open-angle glaucoma, enrolling ~496 participants with visual-field change as the primary endpoint — a key test of whether early surrogate signals translate to preserved vision. * **Glaucoma (second confirmatory trial):** The [Glaucoma Nicotinamide Trial (NCT05275738)](https://clinicaltrials.gov/study/NCT05275738) is a randomized study of ~660 participants assessing visual-field progression, adding independent confirmation of the retinal-protection hypothesis. * **Skin-cancer chemoprevention in transplant recipients (pivotal phase III):** The [Nicotinamide Chemoprevention for Keratinocyte Carcinoma trial (NCT05955924)](https://clinicaltrials.gov/study/NCT05955924) is a phase III study of ~396 solid-organ transplant recipients measuring time to first biopsy-confirmed keratinocyte carcinoma — directly probing the conflicted immunosuppressed population where earlier evidence was negative. * **Inflammatory bowel disease (controlled-release nicotinamide):** The [CICR-NAM ulcerative colitis trial (NCT06488625)](https://clinicaltrials.gov/study/NCT06488625) is a phase II/III study of an oral controlled-ileocolonic-release nicotinamide in ~459 patients with mild-to-moderate ulcerative colitis, testing a novel anti-inflammatory application. * **Future directions that could strengthen the case:** Confirmatory glaucoma and dermatology outcomes, and better human data on tissue NAD+ elevation, could solidify targeted uses; the skin-cancer meta-analysis by [Tosti et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38201930/) frames where additional randomized data are most needed. * **Future directions that could weaken the case:** A negative pivotal transplant trial would narrow the chemoprevention claim, and the broad NAD+ review by [Gallagher & Emmanuel, 2026](https://pubmed.ncbi.nlm.nih.gov/41655607/) underscores how thin human longevity evidence remains; the safety-focused synthesis by [Mainville et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35134311/) will guide dose-limiting concerns as higher-dose uses expand. ## Conclusion Niacinamide is a cheap, generally well-tolerated form of vitamin B3 that the body turns into a coenzyme central to energy production and DNA repair. Its clearest, best-supported uses are correcting vitamin B3 deficiency and, in high-risk people with prior sun-related skin cancers, lowering the rate of new non-melanoma skin cancers at ordinary oral doses — though that skin-cancer benefit did not hold up in organ-transplant recipients, showing it likely depends on the person's immune status. Applied to the skin, it offers modest improvements in barrier, oiliness, and dark spots. Its use for eye and kidney conditions is promising but still being tested in large trials, and its popular billing as a systemic longevity booster rests mainly on laboratory reasoning rather than convincing human results; at high doses it may even blunt some of the very pathways longevity users hope to switch on. Most meaningful risks — stomach upset, liver strain, depletion of methyl groups, and low platelets in kidney-disease dosing — cluster at multi-gram intakes, so lower doses carry a favorable balance. The evidence base is mixed in quality: strong for a few targeted uses, thin and uncertain for the broadest longevity claims, warranting measured expectations. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**